Published in J Biol Chem on June 13, 2001
Optimizing protein stability in vivo. Mol Cell (2009) 2.15
Development of a cytokine analog with enhanced stability using computational ultrahigh throughput screening. Protein Sci (2002) 1.01
Aggregation of granulocyte-colony stimulating factor in vitro involves a conformationally altered monomeric state. Protein Sci (2005) 0.96
Modulation of protein aggregation by polyethylene glycol conjugation: GCSF as a case study. Protein Sci (2006) 0.95
Enthalpic and entropic contributions mediate the role of disulfide bonds on the conformational stability of interleukin-4. Protein Sci (2006) 0.87
The unique cysteine knot regulates the pleotropic hormone leptin. PLoS One (2012) 0.84
Pierced Lasso Bundles are a new class of knot-like motifs. PLoS Comput Biol (2014) 0.83
pH Dependence of structural stability of interleukin-2 and granulocyte colony-stimulating factor. Protein Sci (2003) 0.82
Process development for production of human granulocyte-colony stimulating factor by high cell density cultivation of recombinant Escherichia coli. J Ind Microbiol Biotechnol (2008) 0.80
Antiapoptotic effects of Phe140Asn, a novel human granulocyte colony-stimulating factor mutant in H9c2 rat cardiomyocytes. BMB Rep (2012) 0.76
Cytokine refacing effect reduces granulocyte macrophage colony-stimulating factor susceptibility to antibody neutralization. Protein Eng Des Sel (2015) 0.75
Ubiquitin fusion expression and tissue-dependent targeting of hG-CSF in transgenic tobacco. BMC Biotechnol (2011) 0.75
pH responsive granulocyte colony-stimulating factor variants with implications for treating Alzheimer's disease and other central nervous system disorders. Protein Eng Des Sel (2015) 0.75
Improved drug-like properties of therapeutic proteins by directed evolution. Protein Eng Des Sel (2012) 0.75
Maternal obesity and pregnancy outcome: a study of 287,213 pregnancies in London. Int J Obes Relat Metab Disord (2001) 5.97
A thermodynamic scale for the beta-sheet forming tendencies of the amino acids. Biochemistry (1994) 2.98
The modern preventative treatment of recurrent miscarriage. Br J Obstet Gynaecol (1996) 2.90
Cost-effectiveness of magnetic resonance-guided focused ultrasound surgery for treatment of uterine fibroids. BJOG (2008) 2.89
The leukotriene C(4) transporter MRP1 regulates CCL19 (MIP-3beta, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell (2000) 2.76
Regulation of Hsp90 ATPase activity by tetratricopeptide repeat (TPR)-domain co-chaperones. EMBO J (1999) 2.71
Use of sarcoma 180/TG to prepare hyperimmune ascitic fluid in the mouse. J Immunol (1966) 2.68
An informative protocol for the investigation of recurrent miscarriage: preliminary experience of 500 consecutive cases. Hum Reprod (1994) 2.38
Thrombophilia in pregnancy: a systematic review. Br J Haematol (2006) 2.33
Protein alchemy: changing beta-sheet into alpha-helix. Nat Struct Biol (1997) 2.23
Association of maternal killer-cell immunoglobulin-like receptors and parental HLA-C genotypes with recurrent miscarriage. Hum Reprod (2008) 2.06
The risks associated with pregnancy in women aged 35 years or older. Hum Reprod (2000) 2.06
Modular arrangement of functional domains along the sequence of an aminoacyl tRNA synthetase. Nature (1984) 2.04
Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci U S A (1999) 2.02
Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet (2002) 1.95
Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res (1981) 1.91
Guidelines for protein design: the energetics of beta sheet side chain interactions. Science (1995) 1.88
Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem Pharmacol (2000) 1.87
Redesigning the hydrophobic core of a four-helix-bundle protein. Protein Sci (1994) 1.79
What makes a protein a protein? Hydrophobic core designs that specify stability and structural properties. Protein Sci (1996) 1.76
Recurrent miscarriage. BMJ (1991) 1.72
A systematic exploration of the influence of the protein stability on amyloid fibril formation in vitro. Proc Natl Acad Sci U S A (2000) 1.70
An inverse correlation between loop length and stability in a four-helix-bundle protein. Fold Des (1997) 1.57
Is maternal underweight really a risk factor for adverse pregnancy outcome? A population-based study in London. BJOG (2001) 1.53
Dissecting RNA-protein interactions: RNA-RNA recognition by Rop. Cell (1995) 1.53
Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione. Cancer Res (1997) 1.50
Induction of the differentiation of HL-60 and WEHI-3B D+ leukemia cells by lithium chloride. Leuk Res (1993) 1.46
Factor V Leiden and recurrent miscarriage-prospective outcome of untreated pregnancies. Hum Reprod (2002) 1.42
Glucose production by the human placenta in vivo. Placenta (1999) 1.42
Novel metal-binding proteins by design. Nat Struct Biol (1995) 1.41
Action of the endothelin receptor (ETA) antagonist BQ-123 on forearm blood flow in young normotensive subjects. Clin Sci (Lond) (2002) 1.38
Comparison of DNA lesions produced by tumor-inhibitory 1,2-bis(sulfonyl)hydrazines and chloroethylnitrosoureas. Biochem Pharmacol (2000) 1.37
Differentiation of immortal cells inhibits telomerase activity. Proc Natl Acad Sci U S A (1995) 1.36
Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity. Adv Enzyme Regul (1999) 1.34
1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine (101M): a novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity. Cancer Res (2001) 1.30
Inosinic acid dehydrogenase of sarcoma 180 cells. J Biol Chem (1968) 1.29
Dispensable pieces of an aminoacyl tRNA synthetase which activate the catalytic site. Cell (1984) 1.28
Future pregnancy outcome in unexplained recurrent first trimester miscarriage. Hum Reprod (1997) 1.28
Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins. Cancer Res (1997) 1.27
Obstetric risks of pregnancy in women less than 18 years old. Obstet Gynecol (2000) 1.27
Magnetic resonance-guided focused ultrasound (MRgFUS) compared with abdominal hysterectomy for treatment of uterine leiomyomas. Ultrasound Obstet Gynecol (2009) 1.27
Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess (2006) 1.27
Dramatic structural and thermodynamic consequences of repacking a protein's hydrophobic core. Structure (2000) 1.27
Association of bacterial vaginosis with a history of second trimester miscarriage. Hum Reprod (1996) 1.26
The hypoxic tumor cell: a target for selective cancer chemotherapy. Biochem Pharmacol (1980) 1.24
Amino-acid substitutions in a surface turn modulate protein stability. Nat Struct Biol (1996) 1.22
Antisense oligonucleotides to the p65 subunit of NF-kappa B block CD11b expression and alter adhesion properties of differentiated HL-60 granulocytes. Blood (1993) 1.21
Gonadotrophin-releasing hormone and magnetic-resonance-guided ultrasound surgery for uterine leiomyomata. Obstet Gynecol (2006) 1.20
Reproductive outcomes in women with congenital uterine anomalies detected by three-dimensional ultrasound screening. Obstet Gynecol (2001) 1.19
Magnetic resonance guided focused ultrasound surgery of uterine fibroids--the tissue effects of GnRH agonist pre-treatment. Eur J Radiol (2006) 1.18
Antitumor 2-(aminocarbonyl)-1,2-bis(methylsulfonyl)-1-(2-chloroethyl)- hydrazines. J Med Chem (1996) 1.18
Generation of reactive oxygen radicals through bioactivation of mitomycin antibiotics. Cancer Res (1986) 1.16
A randomized controlled trial comparing medical and expectant management of first trimester miscarriage. Hum Reprod (2004) 1.16
Synthesis and antitumor activity of amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazone. J Med Chem (1992) 1.16
Cancer chemotherapy. Annu Rev Pharmacol (1969) 1.16
Transmuting alpha helices and beta sheets. Fold Des (1997) 1.15
Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro. Antimicrob Agents Chemother (1988) 1.15
Regulation of growth and differentiation of human keratinocytes by type beta transforming growth factor and epidermal growth factor. Cancer Res (1987) 1.15
Comparison of anthracycline concentrations in S180 cell lines of varying sensitivity. Eur J Cancer Clin Oncol (1983) 1.14
Pregnancy outcome is not affected by antiphospholipid antibody status in women referred for in vitro fertilization. Fertil Steril (2000) 1.13
Sidechain interactions in parallel beta sheets: the energetics of cross-strand pairings. Structure (1999) 1.13
Role of lipocortin I in the glucocorticoid induction of the terminal differentiation of a human squamous carcinoma. J Cell Physiol (1990) 1.13
Induction of tumor cell differentiation as a therapeutic approach: preclinical models for hematopoietic and solid neoplasms. Cancer Treat Rep (1986) 1.12
1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): I. Direct inhibition of O6-alkylguanine-DNA alkyltransferase (AGT) by electrophilic species generated by decomposition. Cancer Chemother Pharmacol (2003) 1.12
Enhancement by hyperthermia of the in vitro cytotoxicity of mitomycin C toward hypoxic tumor cells. Cancer Res (1981) 1.12
Reductive activation of mitomycin C by NADH:cytochrome b5 reductase. Cancer Res (1993) 1.11
Endometrial CD56+ natural killer cells in women with recurrent miscarriage: a histomorphometric study. Hum Reprod (1999) 1.10
The 1985 Walter Hubert lecture. Malignant cell differentiation as a potential therapeutic approach. Br J Cancer (1985) 1.10
Surface point mutations that significantly alter the structure and stability of a protein's denatured state. Protein Sci (1996) 1.09
Transcriptional regulation of the vitamin D(3) receptor gene by ZEB. Cell Growth Differ (2001) 1.09
Inhibitors of ribonucleotide reductase. Comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones. Biochem Pharmacol (1994) 1.09
8-Substituted guanosine and 2'-deoxyguanosine derivatives as potential inducers of the differentiation of Friend erythroleukemia cells. J Med Chem (1985) 1.08
1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): II. Role of O6-alkylguanine-DNA alkyltransferase in cytotoxicity. Cancer Chemother Pharmacol (2003) 1.08
Role of NADPH:cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C1. Cancer Res (1984) 1.07
Effect of tumour necrosis factor-alpha and interleukin 1beta on endothelium-dependent relaxation in rat mesenteric resistance arteries in vitro. Br J Pharmacol (2003) 1.06
Effects of adriamycin on surface properties of sarcoma 180 ascites cells. Biochem Pharmacol (1976) 1.06
Effect of alteration of the acetic acid synthesis pathway on the fermentation pattern of escherichia coli. Biotechnol Bioeng (1991) 1.05
Recurrent miscarriage and variant alleles of mannose binding lectin, tumour necrosis factor and lymphotoxin alpha genes. Clin Exp Immunol (2001) 1.05
Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage. Hum Reprod (2001) 1.05
Hypoxia-selective nitrobenzyloxycarbonyl derivatives of 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazines. J Med Chem (1999) 1.04
The role of backbone conformational heat capacity in protein stability: temperature dependent dynamics of the B1 domain of Streptococcal protein G. Protein Sci (2000) 1.04
Recurrent miscarriage--an aspirin a day? Hum Reprod (2000) 1.04
Synthesis and evaluation of 1,2,2-tris(sulfonyl)hydrazines as antineoplastic and trypanocidal agents. J Med Chem (1990) 1.04
Understanding the sequence determinants of conformational switching using protein design. Protein Sci (2000) 1.04
Production of membrane whorls in rat liver by some inhibitors of protein synthesis. J Cell Biol (1974) 1.04
Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells. Cancer Res (1980) 1.03
Polypeptide sequences essential for RNA recognition by an enzyme. Science (1987) 1.02
Modification of the metabolism and cytotoxicity of bioreductive alkylating agents by dicoumarol in aerobic and hypoxic murine tumor cells. Cancer Res (1989) 1.01
The role of membranes in the mechanism of action of the antineoplastic agent adriamycin. Spin-labeling studies with chronically hypoxic and drug-resistant tumor cells. J Biol Chem (1983) 1.01
Induction of the differentiation of HL-60 cells by phorbol 12-myristate 13-acetate activates a Na(+)-dependent uridine-transport system. Involvement of protein kinase C. Biochem J (1991) 1.01
Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia. Haemophilia (2009) 1.01
Aberrations of early trophoblast differentiation predispose to pregnancy failure: lessons from the anti-phospholipid syndrome. Placenta (2005) 1.01
The intracellular location of NADH:cytochrome b5 reductase modulates the cytotoxicity of the mitomycins to Chinese hamster ovary cells. J Biol Chem (1998) 1.00
Aromatic rescue of glycine in beta sheets. Fold Des (1998) 0.99
Characterization of metal binding by a designed protein: single ligand substitutions at a tetrahedral Cys2His2 site. Biochemistry (1995) 0.99
The pharmacological phenotype of combined multidrug-resistance mdr1a/1b- and mrp1-deficient mice. Cancer Res (2001) 0.99
Cellular pharmacology of quinone bioreductive alkylating agents. Cancer Metastasis Rev (1993) 0.99
Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure. Hum Reprod (2002) 0.98